OP 8.4 – 00165 TLR agonist and SIV mAbs administered to SIV-infected ART-suppressed macaques did not delay rebound after treatment interruption
H. King,
D. Brammer,
C. Lehman,
M. Roederer,
D. Bolton,
R. Mason,
K. Song,
K. Foulds,
J. Lifson,
P. Darrah,
R. Geleziunas
Affiliations
H. King
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
D. Brammer
Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
C. Lehman
Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
M. Roederer
Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
D. Bolton
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA
R. Mason
Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
K. Song
Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
K. Foulds
Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
J. Lifson
AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD, USA
P. Darrah
Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
